Loading clinical trials...
Loading clinical trials...
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
Conditions
Interventions
feladilimab (GSK3359609)
GSK3174998
+9 more
Locations
28
United States
GSK Investigational Site
Duarte, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Sarasota, Florida, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
Start Date
June 23, 2016
Primary Completion Date
July 5, 2023
Completion Date
July 5, 2023
Last Updated
December 27, 2024
NCT03206060
NCT06608446
NCT07541924
NCT07542041
NCT04389632
NCT00033137
Lead Sponsor
GlaxoSmithKline
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions